Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $363.4 million.

  • Haemonetics' Cash & Equivalents rose 1325.28% to $363.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $363.4 million, marking a year-over-year increase of 1325.28%. This contributed to the annual value of $306.8 million for FY2025, which is 7156.77% up from last year.
  • Per Haemonetics' latest filing, its Cash & Equivalents stood at $363.4 million for Q4 2025, which was up 1325.28% from $296.4 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Cash & Equivalents ranged from a high of $363.4 million in Q4 2025 and a low of $173.5 million during Q3 2021
  • Its 5-year average for Cash & Equivalents is $262.6 million, with a median of $272.0 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 3714.54% in 2024, then soared by 7156.77% in 2025.
  • Over the past 5 years, Haemonetics' Cash & Equivalents (Quarter) stood at $192.4 million in 2021, then increased by 16.41% to $224.0 million in 2022, then fell by 13.4% to $194.0 million in 2023, then soared by 65.4% to $320.8 million in 2024, then rose by 13.25% to $363.4 million in 2025.
  • Its last three reported values are $363.4 million in Q4 2025, $296.4 million for Q3 2025, and $292.9 million during Q2 2025.